Verona Pharma plc (VRP.L) Share Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma plc (VRP.L) in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Verona Pharma plc (VRP.L) stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRP, but not buy additional shares or sell existing shares.
View analyst ratings for Verona Pharma plc (VRP.L) or view top-rated stocks.

Wall Street analysts have given Verona Pharma plc (VRP.L) a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Verona Pharma plc (VRP.L) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Verona Pharma plc (VRP.L) (LON:VRP) announced its earnings results on Thursday, February, 27th. The company reported ($30.30) earnings per share for the quarter, topping the consensus estimate of ($30.80) by $0.50.
View Verona Pharma plc (VRP.L)'s earnings history.

Verona Pharma plc (VRP.L)'s stock was trading at GBX 49 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VRP shares have increased by 12.2% and is now trading at GBX 55.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Verona Pharma plc (VRP.L) include NexImmune (NEXI), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), Landos Biopharma (LABP), Portage Biotech (PRTG), ProMetic Life Sciences (PLI), Unity Biotechnology (UBX), Open Orphan (ORPH), Kaleido Biosciences (KLDO), Synairgen (SNG), Novacyt (NCYT), Neptune Wellness Solutions (NEPT), Medicenna Therapeutics (MDNA), Decibel Therapeutics (DBTX), Arix Bioscience (ARIX) and Emblem (EMC).
View all of VRP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma plc (VRP.L) investors own include Verona Pharma (VRNA), Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Grifols (GRFS) and Innoviva (INVA).

Verona Pharma plc (VRP.L) trades on the London Stock Exchange (LON) under the ticker symbol "VRP."

Shares of VRP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

One share of VRP stock can currently be purchased for approximately GBX 55.

Verona Pharma plc (VRP.L) has a market capitalization of £228.00 million.

Verona Pharma plc (VRP.L) employs 22 workers across the globe.

The official website for Verona Pharma plc (VRP.L) is www.veronapharma.com.

Verona Pharma plc (VRP.L) is headquartered at 3 More London Riverside, LONDON, SE1 2RE, United Kingdom.

Verona Pharma plc (VRP.L)'s mailing address is 3 More London Riverside, LONDON, SE1 2RE, United Kingdom. The company can be reached via phone at +44-20-32834200.